Alzheimer disease

Related records

Broader conditions (12)

• Central nervous system disorder
• Cognitive disorder
• Dementia
• Disease
• Disease by body system or component
• Disease by developmental or physiological process
• Disease by molecular mechanism
• Human disease
• Nervous system disorder
• Neurodegenerative disease
• Psychiatric disorder
• Tauopathy

Narrower conditions (21)

• Alzheimer disease 10
• Alzheimer disease 11
• Alzheimer disease 12
• Alzheimer disease 13
• Alzheimer disease 14
• Alzheimer disease 16
• Alzheimer disease 17
• Alzheimer disease 18
• Alzheimer disease 19
• Alzheimer disease 2
• Alzheimer disease 3
• Alzheimer disease 4
• Alzheimer disease 5
• Alzheimer disease 6
• Alzheimer disease 7
• Alzheimer disease 8
• Alzheimer disease type 1
• Alzheimer disease without neurofibrillary tangles
• Alzheimer disease, familial early-onset, with coexisting amyloid and prion pathology
• Early-onset autosomal dominant Alzheimer disease

Trials (3,892)

• " The Eyes Have it " : Ocular Saccade Abnormalities in Prodromal Alzheimer's Disease
• "Healthy Actions and Lifestyles to Avoid Dementia or Hispanos y el ALTo a la Demencia Program"
• "Safety in Dementia": An Online Caregiver Intervention
• [11C]MK-6884 Positron Emission Tomography (PET) Tracer Validation Trial (MK-6884-001)
• [18F]-MFBG Versus [123I]-MIBG and [18F]-PE2I in PD vs. MSA and DLB vs. AD
• [18F]ACI-19626 PET in TDP-43 Proteinopathies
• [18F]APN-1607 PET in Subjects With AD Compared to HC
• [18F]AV45(Aβ) and [18F]AV1451(Tau)PET/CT in the Diagnosis of Early Pathological Changes of Alzheimer's Disease
• [18F]F-AraG PET Imaging in Alzheimer's Disease
• [18F]Florbetazine ([18F]92) for Beta Amyloid PET Imaging in Alzheimer's Disease
• [18F]FT8 PET Imaging in Immunoglobulin Light Chain Amyloidosis
• [18F]MC225-PET in Neurodegenerative Disease
• [18F]MK-3328 as a Possible Novel Positron Emission Tomography (PET) Tracer for the Detection of Brain Amyloid Plaques (MK-3328-002)
• [18F]MK-6240 Positron Emission Tomography (PET) Tracer First-in-Human Validation Study (MK-6240-001)
• [18F]NIDF PET Imaging in Tau-related Diseases
• [18F]PI-2620 Phase 3 Histopathological Study
• [18F]THK-5351 Positron Emission Computed Tomography Study of Normal, Mild Cognitive Impairment, Alzheimer's Disease and Other Neurodegenerative Disease
• 10-Year Survival After Acute Hip Fracture in Patients With Preclinical/Clinical Alzheimer Pathology
• 11C-PIB PET Study in MESA at Columbia University
• 12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension

Approved drugs (13)

• Aducanumab
• Donanemab
• Donepezil hydrochloride
• Florbetaben F18
• Florbetapir F 18
• Flortaucipir F 18
• Flutemetamol F 18
• Galantamine hydrobromide
• Ioflupane I 123
• Lecanemab
• Memantine hydrochloride
• Rivastigmine
• Rivastigmine tartrate

Drugs in development (344)

• 2-hydroxypropyl-beta-cyclodextrin Phase 2
• 2,4-dinitrophenol Phase 2
• ABT-126 Phase 2
• ABT-288 Phase 2
• ABT-384 Phase 2
• Acetylcysteine Early phase 1
• Acitretin Phase 2
• Adenosine triphosphate Phase 2
• Alanine Early phase 1
• Albumin human Phase 3
• Aldesleukin Phase 2
• Aleplasinin Phase 1
• Amilomotide Phase 2
• APP-311 Phase 2
• AQW051 Phase 2
• Arginine Phase 2
• Aripiprazole Phase 3
• Arundic acid Phase 2
• Atabecestat Phase 2
• Atomoxetine hydrochloride Phase 2

Other linked drugs (29)

• Acetaminophen
• Alvameline
• Apabetalone
• Berotralstat hydrochloride
• Bifemelane
• BIIB-080
• Bimatoprost
• Cinhyaluronate sodium
• CX-717
• Ergoloid mesylates
• Felcisetrag
• Gadolinium
• Galcanezumab
• Glycopyrronium bromide
• Guanfacine hydrochloride
• Latozinemab
• Lisdexamfetamine dimesylate
• Methylphenidate hydrochloride
• Milacemide
• MK-2461